Elevance Health Stock Weakness Despite Q2 Beat Reflects Medicaid Utilization Pressure, RBC Capital Markets Says

MT Newswires Live07-16 23:03

Elevance Health (ELV) stock price decline despite a Q2 beat and upwardly revised full-year adjusted EPS guidance is primarily due to Medicaid utilization pressure among the continuing member base, RBC Capital Markets said in a research report emailed Thursday.

Planned market exits over the next 18 months could also be cooling expectations around Medicaid recovery momentum, according to the note.

The company's Q2 outperformance was partly driven by Medicare Advantage, alongside an $0.80 per share net benefit related to investment portfolio valuation adjustments, which it will redeploy into accelerated investments in H2, analysts wrote.

The brokerage said it reiterated its sector perform rating on the stock and cut its price target to $424 per share from $439.

Price: 376.68, Change: -13.66, Percent Change: -3.50

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment